REBLOZYL DIN 02505568
Status: Marketed
Holder: BRISTOL-MYERS SQUIBB CANADA
Available to quote
Health Canada record
| Active ingredient(s) | LUSPATERCEPT 75 MG |
|---|
| Dosage form | Powder For Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | B03XA06 LUSPATERCEPT |
|---|
| Original market date | 23-Nov-2020 |
|---|
| Current status date | 19-Feb-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Bristol-Myers Squibb Canada — licence 100100, currently licensed, last inspection rating C (2026-03-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing LUSPATERCEPT
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02505541 | REBLOZYL | BRISTOL-MYERS SQUIBB CANADA | Powder For Solution | LUSPATERCEPT 25 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 32959 | 2024-03-26 | New Drug Submission (NDS) | Administrative - Change in Product Ownership |
| 24315 | 2020-09-25 | New Drug Submission (NDS) | |
Request a quote for REBLOZYL
How to read a Canadian DIN record